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Because the use of herbal therapies in the U.S. is escalating, it is essential to be aware of
clinical and adverse effects, doses and potential drug-herb interactions. A consumer poll in
1998 indicated that one-third of respondents use botanical remedies, and nearly one in five
taking prescription medications also used herbs, high-dose dietary supplements or both. An
estimated 15 million adults are at risk for potential adverse interactions involving prescription
medications and herbs or vitamin supplements, yet most practicing physicians have little
knowledge of herbal remedies or their effects. Herbal products are marketed without the proof
of efficacy and safety that the Food and Drug Administration (FDA) requires of drugs. The
Dietary Supplement and Health Education Act of 1994 allocates responsibility to manufac-
turers for ensuring safety and efficacy with no specific requirements to submit documentation.
Manufacturers may state a product’s physiologic effects but may not make claims for the
treatment or cure of specific diseases. Consumers and practitioners have little information
about product safety, contraindications, interactions or effectiveness and are reliant on
manufacturers to provide accurate labeling. Recently, the growing number of foods with herbs
has raised concerns at the FDA, which requires evidence that food additives are safe.
Considering that the growing appeal of herbal remedies is likely to continue, physicians,
particularly cardiologists, must become familiar with the available cardiovascular information
on herbs. This review highlights the existing data on the efficacy, adverse effects and
interactions for herbal therapies that impact on the cardiovascular system. (J Am Coll
Cardiol 2002;39:1083–95) © 2002 by the American College of Cardiology Foundation
Because the use of herbs and herbal therapies in the U.S. is
escalating, it is essential to be aware of clinical and adverse
effects, doses and potential drug interactions. Most practic-
ing physicians have little knowledge of herbal treatments or
adverse effects (1). A consumer poll in 1998, however,
indicated that nearly one-third of respondents use botanical
remedies (2). Moreover, of those who take prescription
medications, nearly one in five uses herbs, high-dose dietary
supplements or both (3), suggesting an estimated 15 million
adults are at risk for adverse interactions involving prescrip-
tion medications and herbs or vitamin supplements. In
addition, the growing demand for soft drinks and foods
with herbal additives greatly expands public exposure. Sales
of such products grew from $20 million to $700 million in
the past three years (4).
BACKGROUND
Herbal products are marketed without proof of efficacy or
safety that the Food and Drug Administration (FDA)
requires of drugs. The Dietary Supplement and Health
Education Act of 1994 assigns responsibility for ensuring
safety and efficacy to manufacturers, with no requirement to
submit documentation of product testing; it does not set
standards for quality control nor require approval before
supplements enter the market (5). Manufacturers may not
make claims for treatment or cure of a disease but may state
a product’s physiologic effects. Consumers have little infor-
mation to make decisions about safety, adverse effects,
contraindications, interactions or effectiveness and must rely
on manufacturers to provide ingredients that are accurately
labeled (6). Recently, the increasing number of foods
containing herbs has raised concerns at the FDA, which
requires evidence that food additives are safe; consequently,
manufacturers have been warned that the safety of herbal
additives must be proven (4).
Many herbal remedies cannot be patented, and manufac-
turers do not expect to recoup the estimated $350 million to
confirm safety and efficacy (7). The National Center for
Complementary and Alternative Medicine (NCCAM), es-
tablished in 1998 at the National Institutes of Health, is
mandated to conduct and advocate research into comple-
mentary medicines and techniques (8). With a limited
budget of $68.7 million for 2000, NCCAM pursues only a
few therapies and techniques being practiced (8). Investi-
gating the efficacy of herbal therapy is complex because
many contain mixtures of compounds and exist in varied
forms (7). Compounds isolated from herbs may have im-
portant pharmacologic activity, but data from isolates may
understate or overstate actions of the herb, and such
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compounds are variably present in specific products (9–12).
Resources on activity, dosages, toxicities, contraindications
and drug interactions of herbal remedies are constrained by
limited research and information.
Experience in other countries. In Germany, the Ministry
of Health established the Commission E, a committee of
doctors, pharmacists, scientists and herbalists to evaluate the
safety, quality and efficacy of herbs (13). Commission E
approves new remedies and publishes monographs with
recommendations on dose, indications, contraindications,
interactions and mechanisms (13). Physician prescriptions
for herbs account for more than one-half of sales in
Germany, and nearly one-quarter are for cardiovascular
conditions (7). The Commission E reports are widely used
in the U.S. and published by the American Botanical
Council (13). The reference text PDR for Herbal Medicines
is substantially comprised of them (14). In China, there are
two parallel government-supported systems of medicine
(15). Traditional Chinese medicine (TCM) comprises a
variety of remedies including herbs, acupuncture, acupres-
sure and other techniques (15). Patients seek care from
TCM practitioners, or practitioners trained in Western
medicine, and many institutions offer both (16). Research is
supported in each system; however, controlled trials are
lacking because use of a placebo is considered unethical (15).
CARDIOVASCULAR BENEFITS AND ADVERSE
EFFECTS OF COMMON HERBAL THERAPIES
Several herbs offer potential for cardiovascular conditions
including venous insufficiency, intermittent claudication,
hyperlipidemia, hypertension and congestive heart failure
(CHF) (Table 1). Varied mechanisms, including antioxi-
dant, antiplatelet, fibrinolytic, antiatherosclerotic, antihy-
perlipidemic, antiarrhythmic and vasodilatory actions, are
Abbreviations and Acronyms
CHF  congestive heart failure
CNS  central nervous system
FDA  Food and Drug Administration
HDL  high-density lipoprotein
INR  international normalized ratio
LDL  low-density lipoprotein
LV  left ventricular
MI  myocardial infarction
NCCAM  National Center for Complementary and
Alternative Medicine
NYHA  New York Heart Association
PAF  platelet activating factor
PT  prothrombin time
SPICE  Survival and Prognosis Intervention of
Crataegus Extract trial
TCM  traditional Chinese medicine
Table 1. Herbs for Cardiovascular Indications
Herb Indication Evidence Comments
Danshen Ischemic heart disease RCT One small trial reported symptomatic and ECG
improvements (41)
MI NBNRCT Improved outcome, lower mortality (35)
Angina pectoris Animal studies Dilates coronary arteries but constricts noncoronary arteries
at high doses (34,42)
Dong quai Antithrombotic RCT Trial in stroke subjects showed no benefit (160)
Garlic Hyperlipidemia RCT Reduces serum cholesterol 5%–15% (57,64–67)
Hypertension RCT Weak evidence for modest effect (72)
Atherosclerosis RCT Single-trial evidence for reduction in plaque size (90)
Claudication RCT No significant improvement (89)
Ginkgo Cerebrovascular disease RCT Conflicting evidence for improved cognition and memory
(100,103–106)
Claudication RCT Modest improvements in pain-free walking distance (108)
Antioxidation RCT Efficacy in vitro and animal studies (110–112) but no
difference clinically (113)
Ginseng Heart failure NBNRCT Improvements in cardiac function (123–125)
Hypertension NBNRCT Small improvement in systolic blood pressure (126);
however, hypertensive effects have also been described
(127)
Antioxidation RCT One trial reported improved hemodynamics (130)
Hawthorn Heart failure RCT Improvement in symptoms such as fatigue and measures of
cardiac function (139–141). Large trial underway to assess
impact on mortality and disease progression (143)
Hyperlipidemia Animal studies Lowers cholesterol levels, increases LDL receptors (137,138)
Hellebore Hypertension RCT Narrow therapeutic window precludes use (168)
Horse chestnut Venous insufficiency RCT Reduces lower extremity edema and symptoms (148)
Efficacy comparable to compression stockings (150)
Yohimbine Postural hypotension RCT Small trials investigating use in autonomic failure (189)
Erectile dysfunction RCT Weak evidence of efficacy (186)
ECG  electrocardiogram; RCT  randomized, controlled clinical trial; LDL  low-density lipoprotein; MI  myocardial infarction; NBNRCT  trials that were not
placebo-controlled or blinded.
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ascribed to herbs (17). Data from epidemiologic studies
support the potential of dietary antioxidants and flavonoids
(18–21) present in several herbs (22,23) to improve cardio-
vascular health. To date, however, clinical trials with anti-
oxidants such as vitamin E, vitamin A and beta carotene fail
to show clinical benefit (24–29). Herbal remedies may
induce adverse cardiac effects including sympathomimetic
activity, hypertension and arrhythmias (Table 2). Many
interfere with platelet function, and patients at risk for
bleeding or taking antiplatelet drugs should be cautioned
about specific herbs. Physicians must be attuned to interac-
tions between herbs and drugs with a narrow therapeutic
window, such as warfarin and digoxin (Table 3). Adverse
effect data is almost exclusively available as case reports and,
as a result, may be vastly underreported.
Lack of regulation of quality control and of product
standardization makes it difficult to establish safe doses of
herbal products. Active compounds may vary 200-fold
between manufacturers and batches (30). Additives and
contaminants including caffeine, indomethacin and heavy
metals, such as lead, mercury and arsenic, have been found
in herbal remedies (31–33). Misidentification of plants has
led to serious adverse events including renal failure (31).
Considering that the growing appeal of herbal remedies is
likely to continue, physicians, particularly cardiologists,
must become familiar with the available cardiovascular
information on herbs. This review highlights the existing
data on the efficacy, adverse effects and interactions for
herbal therapies that impact on the cardiovascular system.
Danshen (Salvia miltiorrhiza). Danshen is used in TCM
to promote blood flow and treat cardiovascular diseases. It is
sold in over-the-counter herbal preparations, prescribed by
TCM doctors and administered in Chinese hospitals for
angina pectoris (34), acute myocardial infarction (MI) (35)
and ischemic and thrombotic disorders (36). In vitro and
animal studies suggest it may be vasoactive, scavenge free
radicals (37) and inhibit platelet aggregation (38,39). The
active compounds in danshen are tanshinones and phenolic
compounds (34,36).
Danshen has been studied in China for acute MI and
ischemic heart disease (35,40). Most studies are neither
placebo-controlled nor blinded, and often use danshen
Table 2. Herbs With Adverse Cardiovascular Effects
Herb Adverse Effect Comments
Belladonna Tachycardia Herbal source of atropine (92)
Danshen Platelet dysfunction In vitro evidence of platelet antagonism (38,39)
Dong quai Increased bleeding tendency Presence of natural coumarins and in vitro evidence
of platelet antagonism (157,159)
Feverfew Platelet dysfunction In vitro evidence of platelet antagonism (50) not
supported in clinical trials (46,47)
Garlic Increased bleeding tendency Case reports of hemorrhage (61,77). In vitro
evidence of platelet dysfunction (58,73,75) but
conflicting platelet and fibrinolytic evidence from
clinical trials (74,78–82)
Ginger Platelet dysfunction Conflicting results in studies of platelet antagonism
in human trials (163–165)
Hypertension Animal studies of specific purified ginger
compounds demonstrate pressor effects (166,167)
Ginkgo Increased bleeding tendency,
platelet dysfunction
Case reports of central nervous system hemorrhage
(94,95). Pharmacologic evidence of platelet
antagonism; however, active compounds not
present in sufficient amounts in most extracts
(117,118)
Ginseng Hypertension An abuse syndrome involving hypertension is
described in chronic users (127). However,
evidence from clinical trials also supports
hypotensive effects (126)
Hellebore Hypotension, bradycardia Accidental ingestion occurs when plant is mistaken
for another, especially gentian (169,170)
Kava Platelet dysfunction Limited in vitro evidence (174)
Licorice Hypertension, pulmonary edema,
cardiomyopathy (rarely)
Occur as a result of decreased inactivation of
cortisol causing symptoms of mineralocorticoid
excess (179)
Ma huang Stroke, myocardial infarction,
arrhythmia, hypertension
Numerous case reports of serious adverse events in
healthy young people (154)
Myocarditis Rare case report (156)
Oleander Arrhythmia Cardiac glycosides cause symptoms similar to
digoxin toxicity (197,198). Responds to digoxin
antibody treatment (196)
Yohimbine Hypertension, arrhythmia Increases norepinephrine levels and central
sympathetic outflow via 2 antagonism (186,188)
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combined with other herbs. A double-blind study of 67
subjects with ischemic heart disease reported symptomatic
and electrocardiographic improvement with tanshinone
IIA, a compound present in danshen (41). No differences in
cardiac contractility, compliance, inotropy, blood viscosity
or fibrinogen were found. Danshen has been studied for
coronary artery vasodilation, the mechanism underlying its
use in angina (42). At low doses, it causes generalized
vasodilation and decreases blood pressure (42). At higher
doses, however, it causes vasoconstriction in noncoronary
arteries (34,42). Case reports link danshen to warfarin
potentiation (43,44). Animal studies confirm that danshen
decreases warfarin clearance and increases bioavailability
(45).
Feverfew (Tanacetum parthenium). Feverfew is primarily
used for migraine prophylaxis (46). It inhibits platelet
release of serotonin (47) and may have vasoactive effects
(48). The active compound in feverfew, parthenolide, is a
sesquiterpene lactone. Other compounds have been inves-
tigated for biologic activity, most notably flavonoids for a
potential anti-inflammatory effect (49). Feverfew is one of a
few herbs for which data on the content of the active
compounds in commercial preparations are available (12).
Typical daily doses for migraine prophylaxis are 50 to
100 mg of whole or powdered dried leaves, corresponding to
500 g of parthenolide (12,47).
In vitro studies demonstrate that feverfew and partheno-
lide inhibit platelet aggregation and platelet and leukocyte
release of serotonin (46,50). In vitro vasoactive effects vary
with the formulation. Chloroform extracts of fresh leaves
inhibit smooth muscle contractility, but extracts of dried
leaves elicit a contractile response (48,51). Because chloro-
form extracts of dried feverfew do not contain measurable
amounts of parthenolide, other vasoactive compounds may
be present (48). Vasoactive and antiplatelet actions observed
in vitro have not been confirmed in clinical trials (46,47,52–
55).
The most common side effect is mouth ulcers (46).
Feverfew’s inhibition of platelet serotonin release in vitro
raises concerns about interaction with antiserotonin mi-
graine prophylactic drugs (56) and potentiation of bleeding
with antiplatelet agents. However, serious adverse events or
interactions have not been reported.
Garlic (Allium sativum). Estimated mass-market sales of
garlic supplements in 1998 were $84 million (2). Respon-
dents to the third National Health and Nutrition Exami-
nation Survey listed garlic more frequently than other
dietary supplements (5). It is believed to thin the blood,
reduce cholesterol, decrease blood pressure, inhibit athero-
sclerosis and improve circulation.
Randomized clinical trials have been conducted for anti-
hypertensive, antiatherosclerotic and antiplatelet actions,
and intermittent claudication. A recent summary of the data
supporting garlic’s potential in modifying cardiovascular
Table 3. Important Cardiovascular Drug Interactions
Drug Herb Evidence for Interaction
Warfarin Dong quai Case reports of elevation of PT and INR in patient stable on warfarin (157).
Demonstration of pharmacological interaction in rabbits (158).
Danshen Decreases warfarin clearance and increases bioavailability (45). Case reports
of hemorrhage in subjects on warfarin (43,44).
Garlic Rare reports of elevation in INR in subjects previously stable on warfarin
(62). No other supporting data (63).
Ginkgo Case report of CNS hemorrhage in patient previously stable of warfarin
(97). No other supporting data (63).
Ginseng Case report of decreased INR in patient stable on warfarin (131). No other
supporting data (63).
Antiplatelet drugs (NSAIDs, ticlopidine, others) Dong quai In vitro evidence of platelet antagonism (157).
Feverfew Potential antiplatelet effects (50). No case reports of hemorrhage.
Garlic Case reports of platelet dysfunction with increased bleeding time (61,77).
Conflicting evidence from clinical trials of antiplatelet effects (74,78–82).
Ginger In vitro evidence of antiplatelet activity, but no effects seen in clinical trials
and no case reports of adverse events (162–165).
Ginkgo Case reports of hemorrhage (94–96). In vitro evidence of antiplatelet activity
but no confirmatory evidence in human trials (115–119).
Kava In vitro evidence of platelet antagonism (174).
Digitalis Hawthorn Claims of interaction but no case reports and no pharmacologic data (145).
Herbal laxatives Herbal laxatives such as buckthorn, cascara sagrada and senna can cause loss
of potassium leading to digitalis toxicity (200).
Oleander Contains active cardiac glycosides (197).
St. John’s wort Reduces serum digoxin levels (199).
Siberian ginseng May interfere with assay, does not cause elevated digoxin levels (132,133).
Clonidine Yohimbine Competitive 2-antagonist (186).
Tricyclic antidepressants Yohimbine Antidepressants potentiate pressor effects (190).
Methysergide, pizotifen, other serotonin
antagonists
Feverfew Antagonizes serotonin release, may potentiate the effect of other serotonin
antagonists (56).
CNS  central nervous system; INR  international normalized ratio; NSAID  nonsteroidal anti-inflammatory drug; PT  prothrombin time.
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risk, while generally supporting its usefulness, also empha-
sized the lack of knowledge about active compounds and
mechanisms of action (57). Though garlic is believed to be
beneficial for conditions for which approved drugs are
available, such as hyperlipidemia and hypertension, few
studies compare it to pharmacologic treatments.
Studies of garlic are plagued by methodologic problems
related to active compounds. The active substance is allicin,
formed by the action of alliinase on alliin when garlic is
crushed (58). Allinase is inactivated by acid pH, heat and
extraction in organic solvents (59). Thus, garlic’s effects are
dependent on whether it is cooked or in aqueous, oil or
organic extracts (58,59). In addition to allicin, other active
compounds in garlic include methyl allyl trisulfide, diallyl
trisulfide, diallyl disulfide and ajoene (58–60). Its charac-
teristic odor (60) is associated with the active compounds,
which limits blinding in clinical trials. Most studies use
commercially available dried garlic powder standardized for
allicin content, in doses of 300 to 900 mg/day. However,
even standardized products may yield different quantities of
allicin owing to differences in tablet composition (11). Few
trials indicate whether placebo could be differentiated from
active treatment.
Garlic is generally safe and well tolerated; however,
serious adverse events, including central nervous system
(CNS) bleeding (61) and skin burns from topical applica-
tion (57), have been reported. Effects such as flatulence,
dyspepsia, allergic dermatitis and asthma have been de-
scribed (57). Increases in both the prothrombin time (PT)
and international normalized ratio (INR) in subjects previ-
ously stable on warfarin have been attributed to garlic (62);
however, there is little to substantiate the mechanism of the
interaction (63).
HYPERLIPIDEMIA. The antihyperlipidemic effect of garlic
has been extensively studied. Early trials lacked controls,
adequate blinding and dietary monitoring; they were under-
powered or did not analyze results based on intention to
treat (57,64). Recent trials have produced negative findings,
possibly resulting from preparations with reduced bioavail-
ability of allicin (11). Several meta-analyses have summa-
rized data from clinical trials. Each has used different
inclusion criteria, yet the results are consistent across anal-
yses: garlic modestly reduces lipids 15 to 25 mg/dl (5% to
15%) (57,64–67).
The earliest meta-analyses included studies with deficien-
cies (65,66). Warshafsky et al. (65) reported a reduction in
serum cholesterol of 23 mg/dl (9% from baseline) (65).
Silagy and Neil (66) reported lipid reduction of 12% and
provided a subgroup analysis of trials that utilized nonpow-
der forms (i.e., raw, oil or extract). Lipids were reduced by
15% in this subgroup; however, three of five studies were
not double-blind and two were not placebo-controlled.
Stevinson et al. (67) selected only randomized, placebo-
controlled trials of hypercholesterolemic subjects and re-
ported a reduction of only 15.7 mg/dl (4% to 6% reduction).
A subgroup analysis of studies with the highest scores for
methodologic quality found no difference between garlic
and placebo.
Most recently, Ackermann et al. (57) reported a compre-
hensive meta-analysis of garlic trials, showing a reduction in
cholesterol of 17 mg/dl. Subgroup analyses of trials includ-
ing only hyperlipidemic subjects and double-blind trials did
not differ. In contrast to Silagy and Neil (66), subgroup
analysis of trials employing standardized dried garlic powder
preparations showed a slightly improved reduction in cho-
lesterol of 19 mg/dl. This analysis also reported a dose
duration effect of garlic.
A trial of garlic versus a fibrate drug for hyperlipidemia
reported similar efficacy (68). Treatment with dried garlic
powder tablets (900 mg/day) reduced total serum choles-
terol levels from 282 mg/dl to 210 mg/dl over 12 weeks
while bezafibrate (600 mg/day) reduced cholesterol from
287 mg/dl to 208 mg/dl. Both treatments produced parallel
reductions in low-density lipoprotein (LDL) and increases
in high-density lipoprotein (HDL) cholesterol. There was a
trend toward greater reduction in serum triglycerides with
bezafibrate (42% vs. 29%).
HYPERTENSION. In vitro evidence suggests garlic reduces
blood pressure by inhibiting platelet nitric oxide synthase
(69). Many clinical trials, however, find no significant
antihypertensive effect despite form, dose or duration of
treatment. Studies evaluating hypertensive subjects report a
modest reduction in diastolic pressure (70–72). A small,
open-label trial reported that large doses of garlic powder
(2,400 mg) lowered blood pressure 7/16 mm Hg. Only the
diastolic pressure decreased significantly (70). In a placebo-
controlled, double-blind study of 47 hypertensive subjects
only the diastolic pressure decrease (13 mm Hg) was
significant (71). A meta-analysis reported a modest systolic
reduction of 7.7 mm Hg and diastolic reduction of 5.0 mm
Hg (72), but only two trials involved hypertensive subjects.
COAGULATION. Blood-thinning properties are attributed to
enhanced fibrinolytic and antiplatelet activity. There is no
consensus as to the mechanism of fibrinolytic activity. In
vitro and animal studies support several mechanisms for
garlic’s antiplatelet effects. Diallyl disulfide and diallyl trisul-
fide inhibit thromboxane synthesis (58,73), possibly by
inhibiting phospholipase-A and mobilizing arachidonic acid
(74). Extract of raw garlic contains compounds that inhibit
cyclooxygenase (75) and ajoene, a compound in alcohol
extracts of garlic, may inhibit binding of fibrinogen to
platelet receptors (76). Ajoene, however, is not found in
most garlic preparations (59,60).
Garlic’s anticoagulant properties have been linked to
reports of bleeding (61,77); however, clinical trials find
conflicting results (74,78–82). Dried garlic powder de-
creased platelet aggregation in three controlled trials
(78,80,81). Conversely, no difference was found in platelet
aggregation or thromboxane levels in 14 healthy men (82).
Several trials describe increased fibrinolytic activity, and two
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report elevation of tissue plasminogen activator (80,83–85).
However, a trial using garlic powder in patients with
hyperlipoproteinemia found no change in bleeding time,
fibrin split products or clot lysis time (86).
ATHEROSCLEROSIS. The antiatherosclerotic activity of gar-
lic is attributed to cholesterol lowering, but in vitro and
animal studies also support effects independent of lipid
levels, possibly by inhibition of lipid peroxidation (87,88).
Two clinical trials report benefits in atherosclerotic condi-
tions. In subjects with peripheral arterial occlusive disease,
pain-free walking distance improved 46 meters with garlic
compared to 31 meters with placebo (81). Though the mean
difference in walking distance between groups increased,
change in walking distance within each group was not
significant (89). Garlic administered for 48 months reduced
atherosclerotic plaque at the femoral artery or carotid
bifurcation by 5% to 18% (90). Notably, 23% of subjects
taking garlic versus 3% on placebo withdrew owing to odor,
underscoring the difficulty of blinding in garlic trials.
Ginkgo (Ginkgo biloba). Ginkgo biloba, the best-selling
herbal remedy in the U.S. (2), is derived from the leaves of
the maidenhair tree. It is used for cognition and memory as
well as cerebrovascular disease, peripheral vascular disease,
sexual dysfunction, affective disorders, multiple sclerosis,
retinal disorders and hearing loss. The mechanisms by
which ginkgo and its constituent compounds improve vas-
cular health include free radical scavenging, antiplatelet
actions, anti-inflammatory actions, vasodilation and de-
creased blood viscosity. Gamma-aminobutyric acid receptor
agonism and inhibition of monoamine oxidase-B have also
been investigated. Active isolates of ginkgo fall into two
classes: flavonoids and terpenoids. An extract standardized
for flavonoid and terpenoid content, EGb761, is available.
Typical doses are 120 to 160 mg/day (91). Commission E
recommends 120 to 240 mg extract two to three times daily
for cerebral insufficiency (92). Common side effects are
nausea, dyspepsia, headache and allergic skin reactions
(91,93). More serious adverse effects, including spontaneous
subdural hematomas (94), intracerebral hemorrhage (95)
and hyphema (96), as well as warfarin and trazodone
interactions, have been described (97,98).
VASCULAR DEMENTIA. Ginkgo may benefit cerebrovascular
disease by improving blood flow, reducing ischemia-
reperfusion injury or inhibiting platelets (91,99,100). Most
trials of ginkgo enroll patients with cognitive impairment
due to diverse etiologies (101,102). Few enroll patients with
only vascular dementia, and these trials report conflicting
results. A double-blind, placebo-controlled trial of acute
ischemic stroke showed no benefit with ginkgo (100).
Similarly, there was no difference in a trial of 52 subjects
with vascular dementia who underwent psychometric test-
ing (103). A trial assessing dizziness, motor activity, speech
comprehension and depression reported that only dizziness
improved (104). However, two trials have demonstrated
improvement in measures of cognition, including the
Wechsler Adult Intelligence Scale and Sandoz Clinical
Assessment-Geriatric (105,106).
INTERMITTENT CLAUDICATION. Ginkgo may improve in-
termittent claudication via vasoregulation, platelet antago-
nism and protection against postischemic oxidative damage
(91,93,107). At least 11 randomized, placebo-controlled
trials have been conducted. A meta-analysis of trials of
ginkgo for intermittent claudication reported pain-free
walking distance increased by 34 meters (93). In eight trials
of 415 patients all but one favored ginkgo over placebo,
although only four reported confidence intervals that did
not include zero. None reported serious adverse events. A
meta-analysis of pharmacologic interventions for intermit-
tent claudication similarly concluded that ginkgo improves
pain-free walking distance by 32 meters (108). However,
this effect was modest compared to pentoxifylline (208
meters) and naftidrofuryl (101 meters).
ANTIOXIDANT. Evidence from in vitro and animal experi-
ments supports antioxidant activity (91,109,110). Fla-
vonoids constitute about 25% of EGb761 (92) and have
antioxidant and free radical scavenging properties, although
the exact mechanism remains unclear (22). In addition,
bilobalide and ginkgolides A and B are terpenoid com-
pounds selectively studied for protecting ischemic tissue
from reperfusion injury (110–112). Pietri et al. (113)
investigated whether short term pretreatment with high-
dose ginkgo extract (320 mg/day for five days) decreased
reperfusion injury in patients undergoing aortic valve re-
placement. Markers of oxidative stress and cardiac perfor-
mance, including cardiac index and left ventricular (LV)
stroke work, improved after operation; however, clinical
outcomes did not differ.
PLATELET ANTAGONISM. Ginkgo may inhibit platelets and
platelet-induced postischemic inflammatory response by
antagonism of platelet activating factor (PAF), which has
been implicated in reperfusion injury and cardiac dysfunc-
tion in shock (114). Ginkgolide B is a potent inhibitor of
PAF in humans (115,116). Other components of ginkgo
extract have been identified as inhibitors of phospholipase
A2, and thus the production of PAF as well as eicosanoids
(107). However, the compounds attributed with antiplatelet
effects are present in small amounts in most extracts, and
may not produce the same inhibition seen in studies of
isolated compounds (117,118).
No controlled trials in humans confirm ginkgo as an
antiplatelet agent. A placebo-controlled trial of ginkgo
reported no effect on platelet aggregation (119). However,
antiplatelet effects have been cited as the mechanism un-
derlying bleeding events. Two cases of CNS hemorrhage
occurred with ginkgo, 120 to 160 mg/day (94,95). In both,
PT and partial thromboplastin time were normal, but
bleeding time was higher and returned to normal after
ginkgo biloba was discontinued. A case of hyphema oc-
curred after ingestion of ginkgo and aspirin; however, no
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coagulation or bleeding measures were reported (96). In
another patient, previously stable on warfarin, administra-
tion of ginkgo was associated with elevated PT and intra-
cerebral hemorrhage (97).
Ginseng. Ginseng refers to the root of Panax species. The
most commonly examined species are Panax ginseng (Asian
ginseng), Panax quinquefolius (American ginseng) and
Panax japonicus (Japanese ginseng) (120). The terms “red”
and “white” refer to different methods of ginseng prepara-
tion, not different species (121). Siberian ginseng, the root
of an unrelated species, Eleutherococci, does not contain
similar compounds (122). Ginseng is believed to promote
vigor, potency, well-being and longevity. In China it is
utilized for angina pectoris, MI and CHF. It has been
evaluated for many other indications, most notably for use
as an antihyperglycemic. It is administered as a whole dried
root, extract, tea or capsule. The active compounds are
heterogeneous triterpene saponin glycosides, collectively
termed ginsenosides. The exact ginsenosides vary by Panax
species (120), root age (122) and preparation method (i.e.,
red or white) (122). The actions of specific ginsenosides
vary, and in some instances are inconsistent. Of note, many
products that claim ginseng content have no ginsenosides
(9,10). Typical doses are 100 to 400 mg of ginseng extract
daily. The Commission E monograph recommends a dos-
age of 1 to 2 g of root daily (92).
HEART FAILURE. Clinical trials in China and Korea have
investigated ginseng for cardiac function, although there is
no known mechanism and little data from placebo-
controlled or blinded studies. An open trial evaluating CHF
contrasted, 1) red ginseng, 2) digoxin, and 3) digoxin plus
red ginseng, and found that hemodynamic improvement
was most marked with combined therapy (123). An open
trial of Panax notoginseng plus captopril versus captopril
monotherapy in subjects with LV diastolic dysfunction
reported improved diastolic relaxation with the combined
medications (124). In a double-blind, placebo-controlled
trial of coronary heart disease, a mixture of Chinese herbs,
including ginseng, found that stroke volume index and
cardiac index improved (125).
HYPERTENSION. Ginseng has been shown to have both
hypertensive and hypotensive effects in animal studies trials
(122). Hypotensive effects are attributed to enhanced syn-
thesis of nitric oxide (122). An open trial of 4.5 g red
ginseng daily found systolic blood pressure decreased after
eight weeks (126). In contrast, a ginseng-abuse syndrome
has been described wherein hypertension, behavioral
changes and diarrhea occur (127,128). In an observational
study of 133 chronic ginseng users, 22 developed elevated
blood pressure (127). Subjects reported using a variety of
preparations, including some that contained Siberian gin-
seng (128), which has been separately linked with hyper-
tension (129). These conflicting effects are attributed to
diverse actions of particular ginsenosides (122).
ANTIOXIDANT EFFECTS. Animal studies suggest that gin-
seng scavenges free radicals (122). In a placebo-controlled
trial of 30 patients undergoing mitral valve surgery, ginseng
and ginsenoside Rb were evaluated for protective effects in
ischemia and reperfusion injury (130). Both improved
postoperative cardiac function; however, ginseng provided
greater benefit than the isolate ginsenoside Rb.
An interaction of ginseng with warfarin, in which the
INR was reduced to subtherapeutic levels, has been reported
(131). However, no mechanistic evidence for the interaction
has been provided (63). Interaction with digoxin, or with
the digoxin assay and Siberian ginseng (132), has been
observed, though this may have been due to a contaminant
(133). Some ginseng preparations have been contaminated
with germanium, which has led to an account of ginseng-
related diuretic resistance and renal failure (134).
Hawthorn (Crataegus species). Hawthorn is a spiny shrub
native to Europe and North America whose leaves, flowers
and berries are used for CHF. Flavonoids and oligomeric
procyanthins are the active constituents of hawthorn, and an
extract standardized for these compounds, WS 1442, is
available. Proposed mechanisms of action include antioxi-
dant, inotropic, vasodilatory and antihyperlipidemic actions,
as well as decreased capillary permeability (92). Hawthorn
extract (160 to 900 mg two to three times a day for six
weeks) is approved by Commission E for use in New York
Heart Association (NYHA) functional class II CHF (92).
This dose corresponds to 30 to 168.7 mg procyanidins or
3.5 to 19.8 mg flavonoids per dose (92).
Both animal and in vitro studies support several potential
mechanisms of action. Hawthorn extract reduces reperfu-
sion injury in ischemic rat hearts (135). After exposure to
the extract, rat cardiomyocytes show increased inotropy and
a prolonged refractory period (136). Hawthorn, in addition,
decreases plasma lipids and increases hepatic LDL receptor
activity in rats (137,138).
HEART FAILURE. Clinical trials of hawthorn describe de-
creased symptoms of CHF as well as improved cardiac
performance. Several controlled clinical trials report an
improved product of systolic blood pressure and heart rate
measured at rest and during exercise (pressure heart rate
product) (139–141). In an open trial of 1,011 subjects, the
ejection fraction increased and arrhythmias decreased (142).
Other reports indicate that cardiac work tolerance is en-
hanced (92). The first large-scale study designed to look at
mortality, cardiac events and hospitalization is currently
underway (143). The Survival and Prognosis Investigation
of Crataegus Extract (SPICE) trial is investigating WS
1442 for CHF in NYHA functional class II and III. This
randomized, placebo-controlled, double-blind, interna-
tional, multicenter trial will enroll 2,300 subjects by 2002.
Subjects will receive either 450 mg of WS 1442, standard-
ized to contain 84.3 mg procyanidins, or placebo in addition
to standard CHF drugs (digoxin, angiotensin-converting
enzyme inhibitors and diuretics) for 24 months.
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Hawthorn has few adverse effects and no reported drug
interactions (92). Toxicity of WS 1442 has been studied in
animals: doses up to 100 times normal produced no toxic
effects (144). The claim that hawthorn potentiates digoxin
has not been substantiated (145).
Horse chestnut seed (Aesculus hippocastanum). Com-
mission E has approved horse chestnut seed extract for
chronic venous insufficiency (250 to 312 mg extract twice
daily) (92). The active compound, aescin, is a mixture of
triterpene glycosides (92). Aescin decreases lower extremity
edema by decreasing capillary permeability via inhibition of
endothelial lysosomal enzymes and preservation of capillary
wall glycocalyx (146), and venoconstriction via prostaglan-
din F2 (147). Extracts standardized for aescin content are
available, and the Commission E recommends 50 mg aescin
twice daily (92).
A review of eight placebo-controlled trials for venous
insufficiency reported that lower extremity circumference
and volume decreased, and leg pain and pruritus improved
(148). The most frequent adverse effects were gastrointes-
tinal symptoms, dizziness, headache and pruritus. Trials
that compared horse chestnut to hydroxyethylrutosides, a
semisynthetic mixture of flavonoid compounds (149), found
little difference between treatments (148). In a partially
blind study of horse chestnut seed versus compression
stockings or placebo, the volume of lower extremity edema
decreased 45 ml for each active treatment compared to a 10
ml increase for placebo (150).
Side effects include pruritus, nausea, headache and dizzi-
ness (148). There is one reported case of hepatitis from a
commercial preparation of horse chestnut extract,
Venoplant (151). Venocuran, an herbal preparation that
contained horse chestnut, plus phenopyrazone, extracts of
white squill, convallaria, oleander and adonis, was removed
from the market owing to a systemic lupus-like syndrome
(152).
Ma huang (Ephedra sinica). Ma huang is a natural source
of ephedrine and has potent sympathomimetic activity.
Herbal remedies and soft drinks used for energy or weight
loss often contain ma huang. Its pharmacokinetics and
bioavailability are similar to standard doses of ephedrine
(153), but the effects are delayed in onset. Between 1997
and 1999, a total of 140 reports of adverse events were
related to ma huang (154); 13 caused permanent impair-
ment and 10 resulted in death. Many reports concern
healthy young people without known cardiac disease. The
majority had new-onset hypertension, and other findings
included cerebrovascular accidents, arrhythmias and MI.
Several reports link the adverse response of ma huang to
concurrent use of caffeine, guarana (a source of caffeine and
theophylline [155]) or exercise. A case report of eosinophilic
myocarditis possibly associated to ma huang has also been
reported (156).
Other herbs. DONG QUAI ( ANGELICAE SINENSIS). Dong
quai, a TCM remedy for menstrual symptoms and the
menopause (157), is also used for antiarrhythmic, anti-
thrombotic, antiasthmatic and analgesic effects (157–160).
In humans, dong quai has been evaluated for estrogenic
effects (161). Quinidine-like effects have been reported in
animals (159), but not evaluated in clinical trials. Anti-
thrombotic effects are attributed to coumarin derivatives and
ferulic acid contained in the oil of the root (157,159).
Ferulic acid may cause platelet dysfunction by inhibiting
production of thromboxane A2 (157). In a controlled trial of
96 subjects with new cerebral thrombosis or embolism,
there was no difference in improvement rate with dong quai
(160). Case reports of warfarin potentiation have been
reported, and an interaction is supported by animal studies,
which demonstrate alteration of warfarin pharmacodynam-
ics after dong quai (157,158).
GINGER (ZINGIBER OFFICINALE). Dried ginger powder, 500
to 1000 mg, or fresh ginger, 2 to 4 g, is used for nausea
(92,162). Ginger’s alleged vitalizing effect on the heart and
blood is attributed to decreased platelet aggregation and
inhibition of thromboxane synthesis observed in in vitro
studies (162). In vitro antiplatelet activity varies by form
(dried, raw, cooked or extract) (163). Clinical studies,
however, using raw, cooked or dried ginger do not show an
effect on bleeding time, platelet aggregation or thromboxane
production (163–165). Compounds isolated from ginger,
including shogaol and gingerol, have been studied for
positive inotropic and pressor effects (166,167); however, no
clinical trials currently support these effects. Neither adverse
effects nor drug interactions have been reported (92,162).
HELLEBORE (VERATRUM SPECIES). A variety of hellebore
species grow in North America, Europe and Asia and
contain active veratrum alkaloids (168). As a source of
veratrum alkaloids, hellebore’s use as an antihypertensive
was precluded by nausea and vomiting (168). Cardiac
arrhythmias also occur, particularly in association with
digitalis (168). Hellebore toxicity often results from acci-
dental ingestion, particularly when white hellebore (Vera-
trum albums) is mistaken for gentian to produce gentian
wine (169). Toxicity is associated with vomiting, hypoten-
sion and bradycardia, but is rarely fatal (169,170).
KAVA (PIPER METHYSTICUM ). Kava, a member of the black
pepper family, is used by aboriginal peoples of the South
Pacific as an anxiolytic, and it has been promoted to treat
anxiety, depression and muscle tension (171). Sales of kava
products in the U.S. were $8 million in 1998, having grown
more than 450% from the prior year (2). Kava pyrones, the
active compounds in kava (172,173), may inhibit cyclooxy-
genase and thromboxane synthase (174). A small observa-
tional study of an aboriginal community found that HDLs
were higher in kava users (175). Adverse effects include rash,
elevated hepatic enzymes, pulmonary hypertension and
hepatitis (175,176). Kava may also interact with benzodi-
azepines, inducing coma (177).
LICORICE (GLYCYRRHIZA GLABRA). Licorice, an extract of
the root of Glycyrrhiza glabra, is used as a sweetening and
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flavoring agent. It is also used as an herbal remedy for
gastritis and upper respiratory tract infections (178–180).
Most licorice candies in the U.S. do not contain licorice
(181). The active constituent of licorice is glycyrrhizic acid.
A metabolite, glycyrrhetinic acid, inhibits renal 11-
hydroxysteroid dehydrogenase and causes a state of miner-
alocorticoid excess by impeding the inactivation of cortisol
(179). Case reports link licorice to hypertension, hyperten-
sive encephalopathy, pulmonary edema, edema, hypokale-
mia, arrhythmias, CHF, muscle weakness and acute renal
failure (178). Dilated cardiomyopathy resulting from exces-
sive use of licorice and glycyrrhizin for gastritis has been
reported (180). Fifty to 100 g of confectionary licorice, or 50
to 300 mg glycyrrhetinic acid, over weeks may cause adverse
effects (182,183). A study of 30 healthy, normotensive
volunteers reported that 100 g per day of licorice (270 mg
glycyrrhizic acid) over four weeks increased systolic blood
pressure 6.5 mm Hg and decreased plasma potassium 0.24
mmol/l from baseline (184). Susceptibility to licorice varies
greatly; subjects with underlying hypertension and women
may be more sensitive (179,184). Adverse effects may take
weeks to reverse because of suppression of the renin-
angiotensin-aldosterone axis and because glycyrrhetinic acid
has a large volume of distribution (179).
YOHIMBINE (PAUSINYSTALIA YOHIMBE). Yohimbine is iso-
lated from yohimbe, the bark of the tree Pausinystalia
yohimbe, and is used for erectile dysfunction (185). It is a
competitive alpha2-antagonist that increases central sympa-
thetic outflow and raises blood pressure, heart rate and
norepinephrine levels (186–188). As a result, it may exac-
erbate elevated blood pressure in hypertensive patients, as
well as cause arrhythmias and tremors (186,187). Yohim-
bine has been evaluated for use in postural hypotension
associated with autonomic dysfunction (189). As an alpha2-
antagonist, yohimbine opposes the effects of clonidine
(186). It also interacts with tricyclic antidepressants, so that
pressor effects occur at lower doses, and may potentiate the
alpha-adrenergic blocking properties of phenothiazines
(190). Adverse reactions include mania (191), broncho-
spasm (192), a systemic lupus-like syndrome (193) and
agranulocytosis (194). The recommended dose is 5.4 mg
three times daily; pressor effects are associated with doses of
15 to 20 mg (190).
OTHER HERBAL ADVERSE EFFECTS AND DRUG INTERAC-
TIONS. A number of herbs, including oleander, adonis,
black Indian hemp (apocynum), black hellebore, lily-of-the-
valley (convallaria), squill and strophanthus, contain cardiac
glycosides that can potentiate digoxin (195). There are
frequent case reports of toxic ingestion of oleander, a
common flowering shrub found throughout North America
(196–198). Oleander toxicity has been effectively treated
with digoxin-specific antibodies (196). St. John’s wort
(Hypericum perforatum) decreases serum levels of digoxin
through induction of a p-glycoprotein drug transporter
(199). In a single-blind, placebo-controlled study, after 10
days of St. John’s wort, digoxin levels were reduced more
than 25% (199). Several herbs used for a laxative effect, such
as senna, cascara sagrada and buckthorn (200), may aug-
ment potassium loss and lead to toxicity in digoxin users.
Belladonna, an herb used for gastrointestinal symptoms, is a
source of atropine and may cause tachycardia (92).
CONCLUSIONS
The growing use of herbal remedies in the U.S. has far
exceeded the increase in available information on their
benefits, adverse effects and drug interactions. Coherent,
easily accessible data on remedies is lacking. English trans-
lations of the collected German Commission E monographs
represent one of the few references for consumers and
practitioners. Such information is critical to physicians who
often must counsel patients about herbal alternatives to
traditional therapy and address the concern of herb-drug
interactions. Although there is little existing data comparing
herbal therapy to approved drugs, the SPICE trial is a
landmark investigation of an herbal remedy with standard
therapy. With only modest evidence-based data, physicians
may opt to put off interactive questions or refrain from
prescribing herbal remedies. Considering that the escalating
appeal of herbal remedies is likely to continue, such a stance
is impractical and potentially risky for patients. Rather,
another option is that physicians and other health care
providers become familiar with the data and advocate for
greater research and access to information.
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